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andas it shouldbe. This is a conceptual error. Inferiorvenacava
filters are supposed to capture embolized clots, decreasing
symptomatic PEs, and collect thrombuson the inferior side of
the filter, where intrinsic antithromboticmechanisms should
dissolve it. These captured clots should appear in neither the
DVT nor PE totals and should constitute net benefit. Thus, if
IVC filters areworking as intended, DVTs (unembolized clots)
should be unchanged, PEs should be diminished, and total
venous thromboembolisms (VTEs) should be reduced. The
increase in DVTs suggests the prothrombotic effect of IVC
filters.
Second, Dr Hoffer1 notes that we discount the reduction
in “symptomatic” PE in the Prevention du Risque d’Embolie
Pulmonairepar InterruptionCave (PREPIC) study.2,3Wedo for
2 reasons.First, that the reduction inPEdoesnot translate into
any improvement inmortality, and second, PEs in thePREPIC
study were not solely clots causing symptoms, but also clots
elicitedbyannual telephone interviewsand imaging. It is hard
to knowwhat to dowith these “screened”PEs, since it is clear
that themoreyouscan, themore incidental clots canbe found.
There is no doubt that IVC filters increase DVTs. The
PREPIC study, a randomized trial, demonstrates a consis-
tent surplus of DVTs. At 2 years,2 there were 16 more DVTs
in the filter group (37 vs 21). At 8 years, this surplus persists
(57 vs 41), though, as half the population had died, the true
increased risk of DVT may not be fully captured.3 Finally,
population data repeatedly confirms the increased risk of
DVT.4
Third, Dr Hoffer1 cites 2 studies supporting the IVC fil-
ter. Neither is adequate. Stein et al,5 in an inpatient data set,
found that among the 3.4% of patients with PE who were
unstable (International Classification of Diseases, Ninth Revi-
sion codes for shock or ventilator use), those who received
filters did better than those who did not. The authors made
no attempt to correct for baseline differences between these
groups. Thus, the more plausible interpretation of their data
is that in an era where filter use was widespread, unstable
patients with PE, whom physicians elected not to place a fil-
ter, were sicker.
The studybySpencer et al4 is anobservational study, from
which drawing conclusions regarding benefits is tenuous,
though such studies are better at assessing harms. The high-
lighteddifference inPE is likelyduetoascertainmentbias, since
physicians were less likely to scan patients with a known fil-
ter. However, if Dr Hoffer1 believes the reduction in PE is real,
does he also believe the 20% increase in all-cause mortality
among filter users? Interestingly, Dr Hoffer ignores the in-
creased risk of DVT with IVC filters in this study.4
In summary, there remains no good evidence for the ben-
efits of the filter and only clear documentation of harm.
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Exercise, Cardiac Rehabilitation, and
Post–Acute Coronary SyndromeDepression
To the Editor We congratulate Davidson and colleagues1 for
their randomized clinical trial demonstrating that, com-
pared with usual care controls, an active depression treat-
ment program involving problem solving therapy and/or
pharmacotherapy resulted in greater reductions in depres-
sive symptoms in depressed patients with post–acute coro-
nary syndrome (ACS). This work is important in demon-
strating that meaningful improvements in depression can
be achieved with traditional mental health interventions.
However, we were surprised that the potential value of
exercise training (ET) in the routine management of
depressed patients with ACS was not mentioned.
A high prevalence of adverse behavioral characteristics,
includingdepression,hasbeenobserved inpatientswithcoro-
nary heart disease (CHD), particularly post-ACS,withmarked
benefits in these behaviors following ET-based cardiac reha-
bilitation (CR).2,3 In fact, younger patients with CHD (age <55
years) had50%to80%reductions in theprevalenceofdepres-
sion,anxiety, andhostility followingCR,andolderpatientshad
30%to 70% improvements in theprevalenceof these factors.2
In addition, patients with CHDwith symptoms of depression
who attend CR have nearly 70% reductions in 3-year mortal-
ity comparedwith thosewhodidnot attendCR, andonly rela-
tivelymodest improvements in cardiorespiratory fitnesswere
needed to reduce depressive symptoms and improve depres-
sion-related mortality risk.3 A recent single-site randomized
clinical trial demonstrated that ET alone was associated with
significant reductions in depressive symptoms and im-
proved CHD biomarkers in patients with stable CHD and el-
evated depressive symptoms; reduced levels of depression
were comparable to antidepressantmedications, andbothET
and medication use achieved greater reductions in depres-
sioncomparedwithplacebo.4 Inaddition, results fromthemul-
tisite Heart Failure: A Controlled Trial Investigating Out-
comes of Exercise Training (HF-ACTION) trial demonstrated
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that ET resulted in larger reductions in depressive symptoms
relative to usual care in patients with heart failure.5
Although referral of patients with ACS to CR programs is
recommendedbyawide rangeof organizations, including the
American College of Cardiology and the American Heart As-
sociation, theseprogramsare significantlyunderutilized,with
less than20%ofeligiblepatientsparticipating inCR.While cost
and accessibility may discourage referrals, the value of ET-
based CR remains underrecognized and underappreciated.
TherenowiscompellingevidencethatET,especially in thecon-
text of CR, should be incorporated routinely in the secondary
preventionofCHD,particularly inpatientswithpost-ACSwith
symptoms of depression.
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In ReplyWethankLavie and colleagues for their interest in the
resultsofour recentlypublishedComparisonofDepression In-
terventions After Acute Coronary Syndrome (CODIACS) Van-
guard trial,1which showed that depressedpatientswith acute
coronary syndrome (ACS) randomized tocentralized, stepped,
patient-preference depression treatment (psychotherapy or
medication use) had substantially fewer depressive symp-
toms after 6 months compared with those receiving en-
hanced usual care. We also demonstrated that we could de-
liver thisdepression treatmentby telephoneand/orbywebcast
across anumber of different health care settings in geographi-
cally diverse areas. These elements will be vital design com-
ponents of a future phase 3 trial of depression treatment for
patients with ACS.
We agree with Lavie and colleagues that exercise can be
useful as a primary or adjunctive treatment for depression in
patients with ACS. Indeed, Lavie and colleagues have been
leaders in studyingexercise as a treatment fordepression, and
theyare tobecommendedfor their rigorouswork in thisarea.2,3
Moreover, a recent Cochrane systematic review of random-
ized clinical trials in a variety of patient groups showed that
exercise programs are superior to no treatment or to placebo
control conditions for treating depression.4 Nevertheless, we
also agree with Lavie and colleagues that more randomized
clinical trialsof exerciseasa treatment fordepressionafterACS
are needed.
We did not discuss exercise training in the context of
the CODIACS Vanguard trial for several reasons. First, we
enrolled patients with elevated depressive symptoms 2 to 6
months after their ACS, a period when cardiac rehabilita-
tion, which includes exercise, has already been offered. Sec-
ond, we were focused on evaluating a comprehensive
depression treatment that could be delivered in diverse set-
tings, easily, and at modest cost, and that had previously
been found highly acceptable to post-ACS patients, thus
making it readily adoptable for subsequent testing in a
large, multicenter clinical trial.
To our knowledge, there have not been any cost-
effectiveness analyses of exercise for treatingdepression. The
HeartFailure:AControlledTrial InvestigatingOutcomesofEx-
erciseTraining (HF-ACTION) trial,which the letterbyLavieand
colleagues referred to, offered supervised exercise alongwith
intensive education and support and then provided a home
treadmill, all without charge to either the health care system
or the patient.5 Despite these multiple and costly facilitators
of continuingexercise engagement forpatientswithheart fail-
ure, adherence to exercise was marginal; at 1 year, only 38%
of patients in the exercise group were fully adherent.6 Fur-
thermore, as noted by the letter authors, cardiac rehabilita-
tion, which has exercise as a core component, is used by less
than 20% of eligible post-ACS patients. For these reasons, we
didnot includeexercise asoneof the treatmentsoffered inour
study.Differentpatients respond todifferentdepression treat-
ments, so cliniciansmust be prepared to offer a variety of evi-
dence-based treatments for depression after ACS. Exercise
training is indeed a promising candidate, as is the depression
treatment approach tested in the CODIACS Vanguard trial.
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Phenytoin Toxicity Unlikely to Result in Arrhythmias
To the Editor We read with interest the Challenges in Clinical
Electrocardiography case by Johnson et al1 discussing a wide
QRS following liver transplant.Theauthors concluded that this
wasawidecomplextachycardia relatedto fluconazoleandphe-
nytoin toxicity. However, we disagree with the assertion that
the phenytoin contributed to this patient’s arrhythmia. The
clinical course and electrocardiogram are not consistentwith
phenytoin toxicity. Intravenousphenytoinhasbeenknown to
produce cardiovascular collapse when administered too
quickly; however, this is thought to be related to toxicity from
its diluent propylene glycol. In these cases, patients devel-
oped hypotension and bradyarrhythmias.2 Similarly, fosphe-
nytoin use has been described as resulting in hypotension,
bradyarrhythmiasandasystole.3Toourknowledge,widecom-
plex tachycardiashavenotbeendescribed.Twoprevious stud-
ies of phenytoin toxicity (with levels as high as 76 μg/mL) did
not report any wide complex tachycardias or prolongation of
the QRS or QT intervals.4,5 Although phenytoin is a Vaughn-
Williams Class 1B antiarrhythmic, it displays quick on-off ki-
netics at the sodium channel, thusmaking it less arrhythmo-
genic when compared with agents with slow on-off kinetics
suchas the class ICagents. Furthermore, theauthors state that
“the free fraction of phenytoin may have been considerably
higher”1(p955) but report a corrected phenytoin concentration
of 26 μg/mL. This correction estimates the free (pharmaco-
logically active) phenytoin concentration after adjusting it for
the serum albumin concentration. The level reported is only
slightlyabove the therapeutic range.Thus,webelieve thatphe-
nytoin was unlikely responsible for producing this arrhyth-
mia. The exact etiology for the arrhythmias is not apparent.
This was a complex patient with multiple medical problems
and complications. Seizures, however, have also been known
to produce numerous arrhythmias. The follow up electrocar-
diogramprovided appears to demonstrate a prolongedQT in-
terval. Although the initial arrhythmia was not characteristic
of torsadesdepointes, it is possible that fluconazole (or anum-
ber of other medications) or comorbidities could have pro-
duced an arrhythmia.Monomorphicwide complex tachycar-
dia related to fluconazole has not been described but is an
intriguing thought, given that the patient improved with
dialysis. Neither phenytoin nor tacrolimus have pharmacoki-
netics thatwouldmake themamenable tohemodialysis.Thus,
even though phenytoin is classified as both an anticonvul-
sant and an antiarrhythmic, its sodium channel kinetics and
various studies over several decades have shown that phe-
nytoin (parent compound) is unlikely to produce cardiac ar-
rhythmias even in the setting of severe toxicity.
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In ReplyWe appreciate the comments provided by Algren and
Christian, who contend that phenytoin did not contribute to
our presented clinical findings.1
We disagree and are certain that phenytoin use was a
major contributor. The classic findings of high-dose, rapid
phenytoin administration that they describe are inappli-
cable to our patient, who was a complex patient with recent
liver transplant, status epilepticus, and renal failure, in
whom polypharmacy resulted in the electrocardiographic
(ECG) changes.
For example, although bradyarrhythmias have been re-
ported with phenytoin toxicity, this patient was also receiv-
ing dopamine. Second, although our patient’s clinical course
did includehypotension,wechosenot to speculate about cau-
sality fromphenytoin in a patientwith other potential causes
including infection.
The patient most likely had sinus tachycardia. The pro-
longation of the QRS duration was caused by derangement
of ventricular depolarization and repolarization of the heart
due to polypharmacy, including the use of high doses of
intravenous phenytoin. Although Algren and Christian cite 2
older articles2,3 that contend that phenytoin overdose does
not cause QRS and QT prolongation, both articles refer spe-
cifically to oral, not intravenous, overdose. For a variety of
reasons, the effect of an antiarrhythmic agent administered
intravenously may not be the same as the effect of a drug
given orally, even if serum levels are comparable.4 In addi-
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